Jump to main content
Topic: Drug Pricing
-
Association of Rebates in Part D with Patient OOP and Federal Spending
Read More
-
R&D Costs Do Not Explain Elevated U.S. Drug Prices
Read More
-
The U.S. Government Should Buy Gilead for $156Bn to Save Money on Hep C
Read More
-
Value-Based Pricing for Drugs: Theme and Variations
Read More
-
Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs
Read More
-
Overspending Driven by Oversized Single Dose Vials of Cancer Drugs
Read More
-
Pricing in the Market for Anticancer Drugs
Read More
-
Do High Drug Prices Drive Innovation, Or Hurt It?
Read More
-
Could High Drug Prices Be Bad for Innovation?
Read More
-
Unpronounceable Drugs, Incomprehensible Prices
Read More